# Myasthenia Gravis Disease Market

> Myasthenia Gravis Disease Market Research Report: Size, Share, Trend Analysis By Treatment Type (Immunosuppressants, Cholinesterase Inhibitors, Monoclonal Antibodies, Plasmapheresis, Intravenous Immunoglobulin), By Diagnosis Method (Electromyography, Blood Tests, CT Scan, MRI, Edrophonium Test), By Patient Demographics (Adults, Children, Elderly), By Distribution Channel (Hospitals, Pharmacies, Online Stores), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.92%
- **2024:** $ 1,327.42 Million
- **2025:** $ 1,432.55 Million
- **2035:** $ 3,070.01 Million
- **Key Players:** Companies such as Roche (CH), Bristol-Myers Squibb (US), Sanofi (FR), Novartis (CH), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB) are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/4387-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** July 29, 2026

**URL:** https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843

---

## Market Summary

The Global Myasthenia Gravis Disease Market size was valued at USD 1.327 Billion in 2024, and the market is projected to grow from USD 1.433 Billion in 2025 to USD 3.070 Billion by 2035, registering a CAGR of 7.92% during the forecast period 2025–2035. North America led the market in 2024 with over 60.27% share, generating around USD 800 Million in revenue.
 
The increasing prevalence of autoimmune disorders and rapid development of targeted biologics are the primary growth drivers for the Myasthenia Gravis Disease Market. Improved diagnosis, greater disease awareness, and innovative immunotherapies continue accelerating treatment adoption and enhancing long-term patient outcomes worldwide.
 
According to the WHO, noncommunicable diseases account for approximately 43 million deaths annually, representing nearly 75% of global mortality. The growing burden of chronic immune-related conditions continues driving investment in advanced diagnostics, immunology research, and innovative therapies for rare autoimmune diseases such as Myasthenia Gravis.

## Market Drivers

### Market Trends and Projections

The Global Myasthenia Gravis Disease Industry is characterized by various trends that indicate a positive growth trajectory. Current projections suggest that the market will achieve a value of 2.01 USD Billion in 2024, with an anticipated CAGR of 5.96% from 2025 to 2035.
 
This growth is driven by factors such as increasing prevalence, advancements in treatment options, and supportive government policies. The market's expansion reflects the ongoing commitment to improving patient care and developing innovative therapies. As the industry evolves, it is essential to monitor these trends to understand their implications for future market dynamics.
 

- According to the World Bank, global healthcare expenditure continues increasing as countries expand investments in specialized disease management and rare disease care. Growing public and private funding for autoimmune research is supporting development of innovative Myasthenia Gravis therapies, strengthening long-term market expansion and improving patient access to advanced treatments.

### Supportive Government Policies

Government initiatives aimed at improving healthcare access and funding for rare diseases are positively impacting the Global Myasthenia Gravis Disease Industry. Policies that promote research funding and support for clinical trials are essential for advancing treatment options. For example, various countries have established rare disease registries and funding mechanisms to facilitate research.
 
These supportive measures are likely to enhance the development of new therapies, thereby expanding the market. As the industry grows, it is anticipated that the market will reach a valuation of 2.01 USD Billion in 2024, reflecting the positive influence of government involvement in healthcare.
 

- According to PubMed, thousands of rare disease clinical studies are currently indexed worldwide, reflecting expanding government support for orphan drug research and regulatory incentives. Increased funding for autoimmune disease research and accelerated clinical trial programs continue encouraging development of innovative therapies for Myasthenia Gravis patients.

### Growing Awareness and Diagnosis

The Global Myasthenia Gravis Disease Industry benefits from increasing awareness among healthcare professionals and the general public. Enhanced educational initiatives and advocacy efforts are leading to earlier diagnosis and treatment, which is crucial for managing the disease effectively. As more individuals recognize the symptoms and seek medical advice, the number of diagnosed cases is expected to rise.
 
This trend is likely to contribute to the market's expansion, with projections indicating a compound annual growth rate (CAGR) of 5.96% from 2025 to 2035. The focus on early intervention may also lead to improved patient outcomes and reduced healthcare costs.

### Advancements in Treatment Options

Innovations in treatment modalities for Myasthenia Gravis are significantly influencing the Global Myasthenia Gravis Disease Industry. The development of monoclonal antibodies and immunotherapies has transformed patient management, offering more effective and targeted approaches. For instance, therapies such as eculizumab have shown promising results in clinical trials, leading to improved patient outcomes.
 
As these advanced treatments gain regulatory approval and enter the market, they are expected to contribute to the market's growth trajectory, potentially reaching a value of 3.8 USD Billion by 2035. The ongoing research and development efforts indicate a robust pipeline of therapies that may enhance patient quality of life.

### Emerging Markets and Global Expansion

The Global Myasthenia Gravis Disease Industry is experiencing growth in emerging markets, where increased healthcare investments and rising awareness are driving demand for treatment options. Countries in Asia-Pacific and Latin America are witnessing a surge in healthcare infrastructure development, which is likely to enhance access to Myasthenia Gravis therapies.
 
This expansion into new markets presents significant opportunities for pharmaceutical companies. As these regions develop, the market is projected to grow, potentially reaching 3.8 USD Billion by 2035. The increasing focus on healthcare access in these areas may lead to improved patient outcomes and a broader market reach.

### Increasing Prevalence of Myasthenia Gravis

The Global Myasthenia Gravis Disease Industry is witnessing a notable rise in prevalence rates, which is likely to drive market growth. Current estimates suggest that the incidence of Myasthenia Gravis is approximately 20 per 100,000 individuals globally. This increasing prevalence necessitates enhanced healthcare resources and treatment options, thereby expanding the market.
 
As awareness of the disease grows, more patients are diagnosed, contributing to the projected market value of 2.01 USD Billion in 2024. The rising number of patients emphasizes the need for innovative therapies and management strategies, which could further stimulate market dynamics.

## Future Outlook

The Myasthenia Gravis Disease Market size is projected to reach USD 63070.01 Million by 2035, growing at a CAGR of 7.92%, driven by advancements in therapies, increased awareness, and improved diagnostic tools.

**New opportunities:**

- Development of [personalized medicine](https://www.marketresearchfuture.com/reports/personalized-medicine-market-2937) approaches for targeted therapies. Expansion of telehealth services for remote patient monitoring. Investment in AI-driven drug discovery platforms for faster treatment development.

By 2035, the Myasthenia Gravis Disease Market is expected to be robust, driven by innovative solutions and strategic investments.

## Segment Insights

### By Treatment Type: Anticholinesterase Inhibitors (Largest) vs. Monoclonal Antibodies (Fastest-Growing)

The treatment type segment for Myasthenia Gravis shows a diverse distribution among various therapies, including Anticholinesterase Inhibitors, Immunosuppressants, Monoclonal Antibodies, Plasmapheresis, and Intravenous Immunoglobulin. Anticholinesterase Inhibitors remain the dominant therapy, accounting for a substantial 38.6% share of the market due to their established efficacy in symptom management. Conversely, Monoclonal Antibodies are emerging as a fast-growing segment, indicating a shift toward more targeted therapeutic options.

Novartis continues strengthening its neuroscience and immunology portfolio through continuous therapeutic innovation and clinical research. Ongoing investments in autoimmune disease research and targeted treatment development are supporting improved disease management, reinforcing demand for established therapies used in Myasthenia Gravis treatment.

### By Disease Severity: Moderate (Largest) vs. Severe (Fastest-Growing)

The Myasthenia Gravis Disease market is largely segmented by disease severity, with the Moderate category currently holding the largest share, at 47.3%. This prevalence is driven by the growing recognition of symptoms in patients who are experiencing moderate levels of muscle weakness, which comprises a significant segment of those diagnosed. Following closely are the Severe and Crisis segments, which, although smaller in comparison, have also shown considerable numbers amidst patient populations seeking treatment options. The Asymptomatic segment, though not classified under traditional severity scales, indicates a notable presence within the market owing to its crucial role in diagnostics and management of the disease.

Pfizer continues expanding its immunology research through innovative biologic development and strategic collaborations focused on autoimmune diseases. Continuous investment in precision medicine and patient-centered treatment solutions supports improved management of moderate Myasthenia Gravis, contributing to broader adoption of advanced therapeutic approaches.

### By Patient Demographics: Age Group (Largest) vs. Gender (Fastest-Growing)

In the Myasthenia Gravis Disease Market, age demographics significantly shape treatment dynamics. The largest segment, comprising patients aged 50–70, holds a 61.4% share and dominates the patient population, reflecting the typical onset age for the disease. In contrast, younger cohorts, particularly individuals aged 18-35, are emerging as the fastest-growing segment, due to increasing awareness and improved diagnostic practices that facilitate earlier identification of the condition.

Merck & Co. continues advancing immunology and neurological research through innovative drug development and strategic clinical programs. Increasing focus on age-related autoimmune disorders and personalized treatment strategies supports growing demand for effective Myasthenia Gravis therapies among older adult patient populations.

### By Administration Route: Oral (Largest) vs. Intravenous (Fastest-Growing)

In the Myasthenia Gravis Disease Market, the administration route segment reveals a competitive landscape with varying shares. Oral administration currently holds the largest share at 56.8%, driven by significant patient preference due to its ease of use and convenience. Conversely, Intravenous administration is gaining momentum, rapidly capturing market attention owing to its effectiveness in severe cases. Other routes like Subcutaneous and Intramuscular account for a smaller share, primarily chosen based on patient-specific factors and medical guidelines.

Eisai continues investing in patient-centric pharmaceutical innovation with emphasis on convenient oral therapies and neurological disease management. Advancements in oral drug formulations and treatment accessibility continue improving patient adherence while supporting broader adoption of long-term Myasthenia Gravis therapies.

### By Healthcare Setting: Hospital (Largest) vs. Outpatient Clinic (Fastest-Growing)

In the Myasthenia Gravis Disease Market, hospitals account for the largest segment, holding a 64.2% share, as they accommodate the majority of patients requiring intensive treatment and monitoring. They provide comprehensive care resources, including specialized neurologists and access to advanced diagnostic tools, ensuring the best outcomes for patients. Meanwhile, outpatient clinics are rapidly gaining prominence, driven by an increasing preference for less invasive treatments and follow-up care. These facilities support a growing number of patients seeking convenience and specialized care without the need for hospitalization.

AstraZeneca continues expanding collaborations with leading healthcare institutions while advancing innovative therapies for immune-mediated diseases. Ongoing investment in hospital-based specialty care and precision medicine supports increasing utilization of advanced diagnostic services and comprehensive treatment programs for Myasthenia Gravis patients.

## Regional Market Share Analysis

### North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Myasthenia Gravis market, holding a significant share of $800.0M in 2025. The region benefits from advanced healthcare infrastructure, robust research initiatives, and a growing patient population. Regulatory support, including expedited drug approvals, further drives market growth. The increasing prevalence of autoimmune diseases and rising awareness among healthcare professionals are key demand trends fueling this expansion.

- According to the CDC, approximately 3.6 billion laboratory tests are performed annually in the United States, reflecting the country's highly developed diagnostic infrastructure. Amgen continues advancing innovative biologic therapies through ongoing immunology research and strategic collaborations, strengthening treatment options for autoimmune diseases and supporting continued growth of the market across North America.

The competitive landscape in North America is characterized by the presence of major pharmaceutical players such as Roche, Bristol-Myers Squibb, and Pfizer. These companies are actively engaged in developing innovative therapies and expanding their product portfolios. The U.S. remains the leading country, supported by favorable reimbursement policies and a strong focus on research and development. This environment fosters collaboration between industry and academia, enhancing treatment options for patients.

### Europe : Emerging Market with Potential

Europe's Myasthenia Gravis market is projected to reach $350.0M by 2025, driven by increasing healthcare investments and a growing aging population. Regulatory frameworks, such as the European Medicines Agency's initiatives, are facilitating faster drug approvals, which is crucial for addressing unmet medical needs. The rising incidence of autoimmune disorders and enhanced patient awareness are also contributing to market growth, making Europe a key player in the global landscape.

- According to the European Medicines Agency (EMA), more than 100 centrally authorized medicines are scientifically evaluated each year, accelerating patient access to innovative therapies across the European Union. The region's supportive regulatory framework, increasing autoimmune disease research, and expanding investment in rare disease programs continue strengthening adoption of advanced Myasthenia Gravis treatments.

Leading countries in this region include Germany, France, and the UK, where significant investments in healthcare infrastructure are evident. Major pharmaceutical companies like Sanofi and Novartis are actively involved in research and development, focusing on innovative treatment options. The competitive landscape is evolving, with a mix of established players and emerging biotech firms, creating a dynamic environment for growth and collaboration.

### Asia-Pacific : Emerging Powerhouse in Healthcare

The Asia-Pacific Myasthenia Gravis market is estimated at $150.0M in 2025, reflecting a growing awareness of autoimmune diseases and increasing healthcare expenditure. Countries like Japan and Australia are leading the charge, supported by government initiatives aimed at improving healthcare access and quality. The region's diverse population and rising prevalence of chronic diseases are key drivers of market demand, alongside advancements in medical technology and treatment options.

In this competitive landscape, key players such as Eisai and Amgen are making significant strides in developing therapies tailored to regional needs. The presence of a burgeoning biotech sector is fostering innovation, while collaborations between pharmaceutical companies and research institutions are enhancing treatment availability. As regulatory frameworks evolve, the Asia-Pacific region is set to become a vital hub for Myasthenia Gravis treatment advancements.

### Middle East and Africa : Resource-Rich Frontier

The Middle East and Africa Myasthenia Gravis market is valued at $27.42M in 2025, facing unique challenges such as limited healthcare access and varying regulatory environments. However, the region presents opportunities for growth, driven by increasing awareness of autoimmune diseases and improving healthcare infrastructure. Government initiatives aimed at enhancing healthcare services are expected to catalyze market development, despite existing barriers to treatment access.

Countries like South Africa and the UAE are emerging as key players in the market, with a focus on improving patient care and expanding treatment options. The competitive landscape is characterized by a mix of local and international pharmaceutical companies, striving to address the unmet needs of patients. As healthcare systems evolve, the potential for growth in the Myasthenia Gravis market in this region is significant, paving the way for innovative solutions and partnerships.

## Competitive Benchmarking

The Myasthenia Gravis Disease Market is characterized by a dynamic competitive landscape, driven by a confluence of innovation, strategic partnerships, and a growing emphasis on personalized medicine. Key players such as Roche (CH), Bristol-Myers Squibb (US), and Novartis (CH) are actively shaping the market through their distinct operational focuses. Roche (CH) has been particularly aggressive in advancing its research and development initiatives, aiming to enhance treatment efficacy and patient outcomes. Meanwhile, Bristol-Myers Squibb (US) has concentrated on strategic collaborations to bolster its pipeline, indicating a trend towards synergistic partnerships that could redefine therapeutic approaches.
 
Novartis (CH), on the other hand, appears to be leveraging its global footprint to expand access to innovative therapies, thereby enhancing its competitive positioning in this niche market.The business tactics employed by these companies reflect a nuanced understanding of the market's structure, which is moderately fragmented yet increasingly influenced by a few dominant players. Localizing manufacturing and optimizing supply chains have emerged as critical strategies to enhance operational efficiency and reduce costs. This collective approach not only strengthens individual company positions but also contributes to a more resilient market structure, where agility and responsiveness to patient needs are paramount.
In November Roche (CH) announced a groundbreaking partnership with a leading biotechnology firm to co-develop a novel monoclonal antibody targeting specific autoantibodies associated with Myasthenia Gravis. This strategic move underscores Roche's commitment to innovation and its proactive stance in addressing unmet medical needs. The collaboration is expected to accelerate the development timeline, potentially bringing a new treatment option to market sooner than anticipated, thereby enhancing Roche's competitive edge.
In October Bristol-Myers Squibb (US) expanded its clinical trial program for a promising therapy aimed at refractory Myasthenia Gravis patients. This expansion not only reflects the company's dedication to addressing diverse patient populations but also positions it to capture a larger market share as it seeks to establish itself as a leader in this therapeutic area. The strategic importance of this initiative lies in its potential to generate robust clinical data that could support regulatory approvals and subsequent market entry.
In September Novartis (CH) launched a digital health platform designed to facilitate patient engagement and adherence to treatment regimens. This initiative aligns with the growing trend of digitalization in healthcare, aiming to empower patients and improve treatment outcomes. By integrating technology into its therapeutic offerings, Novartis is likely to enhance its value proposition, thereby differentiating itself in a competitive landscape increasingly focused on patient-centric solutions.
As of December the competitive trends within the market are increasingly defined by digital transformation, sustainability initiatives, and the integration of artificial intelligence in [drug development](https://www.marketresearchfuture.com/reports/drug-development-market-66529). Strategic alliances are becoming pivotal, as companies recognize the value of collaborative innovation in navigating complex regulatory environments and accelerating time-to-market for new therapies. Looking ahead, the competitive differentiation is expected to evolve from traditional price-based competition towards a landscape where innovation, technological advancements, and supply chain reliability take precedence. This shift may ultimately redefine how companies engage with healthcare providers and patients, fostering a more integrated and responsive healthcare ecosystem.

## Recent News & Developments

The FDA approved Johnson & Johnson's FcRn-blocking monoclonal antibody, Imaavy (nipocalimab), on April 30, 2025, making it the first to be approved in the United States for the treatment of generalized myasthenia gravis (gMG) in patients 12 years of age and older. This establishes the medication as a crucial therapeutic choice that targets IgG-mediated illness processes.

The FDA authorized Argenx's Vyvgart Hytrulo prefilled syringe on April 10, 2025, allowing adult gMG and CIDP patients to self-administer their efgartigimod/hyaluronidase combo at home. This step is anticipated to increase patient convenience and accessibility.Positive Phase 3 findings from the MINT study, which showed that Uplizna (inebilizumab) significantly improved daily living activities in AChR+ gMG patients during a 52-week period, were announced by Amgen on March 14, 2025.

The FDA authorized the first pediatric treatment for gMG on March 12, 2025, when it extended the use of Soliris (eculizumab) to kids patients six years of age and up. UCB received FDA clearance in October 2023 for Zilbrysq (zilucoplan), a subcutaneous complement C5 inhibitor for adult AChR+ gMG patients.In June 2023, the company introduced Rystiggo (rozanolixizumab), an FcRn modulator for adult gMG that is licensed in the US and the EU. The gMG environment has a strong diversity of treatment approaches, as seen by these recent regulatory accomplishments.

## Report Scope

| MARKET SIZE 2024 | 1327.42(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1432.55(USD Million) |
| MARKET SIZE 2035 | 3070.01(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.92% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Roche (CH), Bristol-Myers Squibb (US), Sanofi (FR), Novartis (CH), Pfizer (US), Merck & Co. (US), Amgen (US), Eisai (JP), AstraZeneca (GB) |
| Segments Covered | Treatment Type, Disease Severity, Patient Demographics, Diagnosis Method, Healthcare Setting |
| Key Market Opportunities | Advancements in targeted therapies and personalized medicine enhance treatment options in the Myasthenia Gravis Disease Market. |
| Key Market Dynamics | Rising demand for innovative therapies drives competitive dynamics in the Myasthenia Gravis Disease market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Myasthenia Gravis Disease Market as of 2024?**
A: The Myasthenia Gravis Disease Market was valued at 1327.42 USD Million in 2024.

**Q: What is the projected market valuation for the Myasthenia Gravis Disease Market in 2035?**
A: The market is projected to reach 3070.01 USD Million by 2035.

**Q: What is the expected CAGR for the Myasthenia Gravis Disease Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Myasthenia Gravis Disease Market during 2025 - 2035 is 7.92%.

**Q: Which treatment type segment had the highest valuation in 2024?**
A: In 2024, the Immunosuppressants segment had a valuation of 450.0 to 1100.0 USD Million.

**Q: How does the market perform across different disease severity segments?**
A: The Severe disease severity segment was valued between 500.0 and 1200.0 USD Million in 2024.

**Q: What are the key demographics influencing the Myasthenia Gravis Disease Market?**
A: Key demographics include Age Group, Gender, and Ethnicity, with valuations ranging from 250.0 to 900.0 USD Million in 2024.

**Q: Which administration route segment is expected to show significant growth?**
A: The Intravenous administration route segment, valued at 450.0 to 1000.0 USD Million in 2024, is expected to show significant growth.

**Q: What healthcare settings are most relevant for Myasthenia Gravis treatment?**
A: In 2024, the Hospital setting was valued between 400.0 and 900.0 USD Million, indicating its relevance.

**Q: Who are the key players in the Myasthenia Gravis Disease Market?**
A: Key players include Roche, Bristol-Myers Squibb, Sanofi, Novartis, and Pfizer, among others.

**Q: What is the potential impact of emerging therapies on the Myasthenia Gravis Disease Market?**
A: Emerging therapies may influence market dynamics, particularly in treatment types like Monoclonal Antibodies, valued at 300.0 to 700.0 USD Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/myasthenia-gravis-disease-market-5843*